Psyence Biomedical Ltd. (PBM) — Psyence Biomedical implemented a previously delayed 1-for-6.25 reverse share consolidation, a step aimed at supporting its Nasdaq listing compliance and share price.
The palliative-care-focused psilocybin developer continued advancing its NPX-5 program for adjustment disorder in cancer patients. Reverse splits were a recurring theme among small-cap psychedelic names navigating exchange minimum-price rules in early 2026.
Source: psyencebiomed.com
For the rest of that week's sector news, read our week in review.